Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096689 | 0.80 | ANPEP (0.53) | TSHRANPEPCA1CA2CA12 | |
| SCHEMBL11747478 | 0.80 | TSHR (0.55) | TSHRTP53SRD5A2ANPEPCA1 | |
| SCHEMBL6132150 | 0.79 | TSHR (0.48) | TSHRTP53SRD5A2ANPEPCA1 | |
| SCHEMBL6969522 | 0.79 | CA1 (0.50) | TSHRCA1CA2CA12CA9 | |
| Carbamic Acid SCHEMBL10434705 | 0.77 | TSHR (0.48) | TSHRSMN1; SMN2CES2CES1 | |
| SCHEMBL236726 | 0.77 | TSHR (0.58) | TSHRALDH1A1 | |
| SCHEMBL77244 | 0.77 | TSHR (0.58) | TSHRALDH1A1 | |
| SCHEMBL235417 | 0.77 | TSHR (0.58) | TSHRALDH1A1 | |
| SCHEMBL10660558 | 0.77 | TSHR (0.63) | TSHRTP53SRD5A2ANPEPCA1 | |
| SCHEMBL4640939 | 0.77 | SRD5A2 (0.68) | TSHRTP53SRD5A2ANPEPCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521727-B1 | NEW BENZOIC PYRROLOPYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARKINSON'S DISEASE | INVENTIVA (FR) | 2014-03-19 | — | — | EP | disclosed |
| CN-103554006-A | Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease | FOURNIER LAB SA | 2014-02-05 | — | — | CN | disclosed |
| EP-2521727-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | Laboratoires Fournier S.A. (FR) | 2012-11-14 | — | — | EP | disclosed |
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
| CN-102596906-A | Use of indole derivatives as NURR-1 activators as agents for the treatment of Parkinson's disease | FOURNIER LAB SA | 2012-07-18 | — | — | CN | disclosed |
| WO-2011083278-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | LABORATOIRES FOURNIER SA (FR) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | TSHR 95/4885TP53 2041/4885SRD5A2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.